COO

Business profile & competitive position

The Cooper Companies, Inc. operates in Healthcare, specifically the Medical – Instruments & Supplies industry, as a global medical device company with headquarters in San Ramon, California. It runs two segments. CooperVision develops, manufactures, and markets single-use, two-week, and monthly contact lenses, including silicone hydrogel lenses, orthokeratology and scleral lenses, and the MiSight 1 day myopia-management lens. CooperSurgical offers more than 600 products and services centered on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation, and genomic services. The company’s products reach over 130 countries and touch more than fifty million lives annually, supported by approximately 500 research-and-development employees across both segments. MiSight 1 day holds the distinction of being the only contact lens approved by the FDA, China’s NMPA, and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children.

The financial signature of the franchise is a 13.5% net margin paired with a 6.9% return on equity. The mid-teens net margin is consistent with a consumable-medical-device business that can command pricing power in specialty lenses and surgical products, but the single-digit ROE suggests the company is not translating that margin into exceptionally high shareholder returns. That combination can indicate meaningful capital intensity—manufacturing, inventory, global distribution, and R&D—alongside a balance-sheet structure that is conservative rather than heavily leveraged. For investors, the implication is a durable revenue base in vision and women’s health, but not a capital-light compounder on the current reported numbers.

Financial posture

Cooper Companies carries an $11.0 billion market capitalization and trades at a 19.7 P/E ratio based on the current price of $57.6483. The 19.7 multiple sits noticeably above the current 6.9% ROE, meaning the market is pricing in improved returns or growth that is not yet visible in trailing equity returns. Net margin of 13.5% provides a floor of profitability, while the 0.82 beta signals below-average sensitivity to broad equity-market swings, consistent with a defensive healthcare name whose products are largely non-disposable-consumer and procedure-linked. The price as of the data snapshot is below its 50-day EMA of $60.75, and the RSI reads 49.0, a neutral level that offers no strong momentum signal either way.

What the valuation gap between P/E and ROE highlights is that the stock is being valued as a growth-and-recovery story rather than a high-return incumbent. The company’s two-segment model—vision plus fertility/women’s health—gives it revenue diversification, yet the low ROE relative to the P/E multiple shows that execution risk is embedded in the price. The financial posture is therefore one of moderate valuation, modest systemic risk, and a profitability base that the market apparently expects to expand.

Strategic priorities & outlook

According to the company’s most recent SEC 10-K filing, CooperVision is focused on driving greater worldwide market penetration of recently introduced products and expanding in both existing and emerging markets. That effort is supported by increased investment in distribution and packaging capabilities so the business can scale without losing service quality. A separate, longer-term initiative is the development of the myopia-management market through education aimed at eye care practitioners, patients, and families, leveraging the first-mover regulatory position of MiSight 1 day.

On the CooperSurgical side, the stated priority is to keep investing in the business, including through strategic transactions, in order to expand its integrated solutions model within fertility and women’s health. That acquisition-led, platform-building approach is meant to deepen customer relationships across the clinical continuum rather than relying on single-product sales. The filing also flags the global footprint—products sold in over 130 countries and a claim of positively impacting more than fifty million lives each year—as a structural theme under both segments.

Macro & geopolitical exposure

As a Medical – Instruments & Supplies company, Cooper Companies sits at the intersection of healthcare regulation, global trade, currency markets, and demographic trends. Contact lenses and fertility/women’s health devices are subject to approvals and oversight by bodies such as the FDA and foreign equivalents, so regulatory risk is inherent to the industry. With sales in more than 130 countries, foreign-exchange exposure is a meaningful variable: a stronger U.S. dollar pressures translated revenue and margins, while a weaker dollar can flatter them.

Trade policy and supply-chain considerations also matter for the sector. Medical devices and their packaging materials can face tariffs or import restrictions, and manufacturing footprint decisions affect cost structures. Commodity input costs for plastics and packaging materials can move with energy and petrochemical prices, though these are generally manageable for larger operators. On the demand side, fertility and vision care can be influenced by reimbursement policies, public health coverage, and broader economic conditions, because some CooperSurgical services and even contact-lens purchases carry out-of-pocket components. None of these are company-specific claims; they are sector-level realities implied by the Medical – Instruments & Supplies classification.

Recent developments

Over the four trading days from October 15 to October 18, 2026, a cluster of headlines around Cooper Companies concentrated on investor-relations activity rather than operational news. On October 15, Newsfile reported that Rosen Law Firm, “leading investor counsel,” encouraged The Cooper Companies investors to inquire about a securities class-action investigation. On October 16, a Globenewswire release urged investors who suffered losses to contact Rosen Law Firm about their rights. On October 17, Newsfile carried another Rosen release framing the firm as “a longstanding law firm” and again encouraging inquiries about the same investigation. Finally, on October 18, PR Newswire published a similar Rosen Law Firm notice. These items do not state that a class action has been filed, but they create headline risk and can weigh on sentiment, especially when they cluster in a short window ahead of an earnings report.

Earnings behavior & post-earnings drift

Cooper Companies’ recent earnings record is mathematically strong but behaviorally complicated. Over the last eight reported quarters, the company beat consensus earnings estimates every time, for a 100% beat rate, with an average earnings surprise of 4.2%. Yet the average 5-day price move after those reports is -2.34%, classified as a downward drift. That is the textbook definition of a disconnect between accounting outperformance and market reaction: beating estimates has not reliably produced a sustained price pop during the following week.

The most recent four quarters illustrate the point in detail. On September 9, 2026, COO reported EPS of $1.15 against a $1.12 estimate, a 2.7% beat, but the stock fell 14.67% the next day and finished the following five sessions down 13.97%. On June 4, 2026, actual EPS was $1.21 versus $1.10 estimated, a 10% surprise, and the stock rallied 8.58% the next day and 8.85% over the next five days. On March 5, 2026, a $1.10 print against $1.03, a 6.8% beat, was followed by a 4.55% next-day drop and a 10.82% five-day decline. On December 4, 2025, the company earned $1.15 against $1.11 estimated, a 3.6% beat, and the stock rose 5.67% the next day and 6.59% over the following five sessions.

The pattern is not linear: a larger beat in June produced a rally, while a smaller beat in September produced a severe selloff. This means the market’s real expectation may incorporate forward guidance, segment margins, currency commentary, or litigation developments that are not captured by the EPS number alone. The next scheduled report is December 3, 2026, after the market close, with a consensus EPS estimate of $1.07. Historical beat-rate and surprise figures are descriptive, not predictive; the takeaway is that post-earnings price action around COO should be judged over a multi-day window and with attention to guidance, not just the headline beat or miss.

For a deeper dive into the full institutional verdict on Cooper Companies, including aggregated analyst estimates, model revisions, and institutional-positioning context, readers should consult the platform’s complete research dashboard rather than relying on any single earnings snapshot.